Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
The spectrum of MOG autoantibody-associated demyelinating diseases.
Anti-JC virus seroprevalence in a Finnish MS cohort.
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States.
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue.
Epstein-Barr virus latent membrane protein 2A exacerbates experimental autoimmune encephalomyelitis and enhances antigen presentation function.
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.
The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
DMDs Are an Essential Issue But Are They the Only Issue in MS Treatment?
[Epstein-Barr virus in the pathogenesis of multiple sclerosis (a review).]
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
Strategies for myelin regeneration: lessons learned from development.
The autonomic balance predicts cardiac responses after the first dose of fingolimod.
Pregnancy and Multiple Sclerosis (MS): A Beneficial Association. Possible therapeutic application of embryo-specific Pre-implantation Factor (PIF*).
Severe dystonia as the first manifestation of neuromyelitis optica.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Oral contraceptive use and clinical outcomes in patients with multiple sclerosis.
Diagnostic Ability of a Linear Discriminant Function for Spectral-Domain Optical Coherence Tomography in Patients with Multiple Sclerosis.
Serum level of interleukin-6 in Chinese patients with multiple sclerosis.
T Cell-Intrinsic Function of the Noncanonical NF-κB Pathway in the Regulation of GM-CSF Expression and Experimental Autoimmune Encephalomyelitis Pathogenesis.
Microparticle Platform
UCSF Neuroimmunology Research Seminar
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
Pages
« first
‹ previous
…
194
195
196
197
198
199
200
201
202
…
next ›
last »